...
首页> 外文期刊>European review for medical and pharmacological sciences. >Teriparatide alleviates osteoporosis by promoting osteogenic differentiation of hMSCs via miR-375/RUNX2 axis
【24h】

Teriparatide alleviates osteoporosis by promoting osteogenic differentiation of hMSCs via miR-375/RUNX2 axis

机译:特立帕肽通过miR-375 / RUNX2轴促进hMSC的成骨分化来缓解骨质疏松

获取原文
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: To investigate whether Teriparatide (TP) contributed to the osteogenic differentiation of human marrow mesenchymal cells (hMSCs) through the regulation of miR-375, thereby alleviating osteoporosis (OP). PATIENTS AND METHODS: The expression levels of miR-375 in the serum and hMSCs of patients with OP were determined by quantitative real time-polymerase chain reaction (qRT-PCR). hMSCs were extracted from bone marrows of OP patients and underwent osteogenic differentiation for 1 day, 3 days, 7 days and 10 days, respectively. The mRNA levels of alkaline phosphatase (ALP), osteocalcin (OCN) and runt-related transcription factor 2 (RUNX2) in TP-treated hMSCs transfected with miR-375 mimics or negative control were detected by qRT-PCR. Western blot was conducted to determine the protein expression of RUNX2 in TP-treated hMSCs transfected with miR-375 mimics or negative control. Besides, the osteogenic capacity and mineralization capacity of hMSCs were evaluated by the detection of ALP activity, ALP staining and Alizarin red staining, respectively. Dual-Luciferase reporter gene assay was performed to verify the binding between RUNX2 and miR-375. Subsequently, RUNX2 expression was detected in hMSCs transfected with miR-375 mimics or inhibitor. Rescue experiments were finally performed to determine whether miR-375 was involved in TP-induced osteogenic differentiation by targeting RUNX2. RESULTS: MiR-375 remained at a high level in serum of OP patients, while gradually decreased with the prolongation of osteogenic differentiation in isolated hMSCs. TP induction increased the osteogenic and mineralization capacities of hMSCs, which were inhibited after miR-375 overexpression. Through Dual-Luciferase reporter gene assay, we confirmed the binding relationship between miR-375 and RUNX2. Besides, both mRNA and protein levels of RUNX2 were negatively regulated by miR-375. Finally, we verified that co-overexpression of miR-375 and RUNX2 in TP-induced hMSCs significantly enhanced the mineralization capacity compared to overexpression of miR-375 alone. CONCLUSIONS: Teriparatide promoted the osteogenic differentiation of hMSCs through miR-375/RUNX2 axis.
机译:目的:探讨特立帕肽(TP)是否通过调节miR-375来促进人骨髓间充质细胞(hMSCs)的成骨分化,从而减轻骨质疏松症(OP)。病人和方法:通过定量实时聚合酶链反应(qRT-PCR)测定OP患者血清和hMSCs中miR-375的表达水平。从OP患者的骨髓中提取hMSC,分别进行1天,3天,7天和10天的成骨分化。通过qRT-PCR检测转染miR-375模拟物或阴性对照的TP处理的hMSC中碱性磷酸酶(ALP),骨钙素(OCN)和矮子相关转录因子2(RUNX2)的mRNA水平。进行蛋白质印迹分析以确定在用miR-375模拟物或阴性对照转染的TP处理的hMSC中RUNX2的蛋白表达。此外,分别通过检测ALP活性,ALP染色和茜素红染色来评估hMSC的成骨能力和矿化能力。进行双荧光素酶报道基因检测以验证RUNX2和miR-375之间的结合。随后,在用miR-375模拟物或抑制剂转染的hMSC中检测到RUNX2表达。最终进行了抢救实验,以确定miR-375是否通过靶向RUNX2参与TP诱导的成骨分化。结果:OP患者的血清中MiR-375保持较高水平,而随着分离的hMSCs成骨分化的延长而逐渐降低。 TP诱导增加了hMSCs的成骨和矿化能力,在miR-375过表达后被抑制。通过双荧光素酶报告基因检测,我们证实了miR-375与RUNX2之间的结合关系。此外,miR-375对RUNX2的mRNA和蛋白质水平均具有负调节作用。最后,我们证实与单独的miR-375的过表达相比,TP诱导的hMSC中miR-375和RUNX2的共过表达显着增强了矿化能力。结论:特立帕肽通过miR-375 / RUNX2轴促进hMSCs的成骨分化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号